The role of hippocampal KCNQ2 channel in antidepressant actions of ketamine
- PMID: 35863316
- DOI: 10.1016/j.neuron.2022.05.027
The role of hippocampal KCNQ2 channel in antidepressant actions of ketamine
Abstract
In this issue of Neuron, Lopez et al. report that KCNQ2 (potassium voltage-gated channel subfamily Q member 2) is essential for the sustained antidepressant-like effects of ketamine in glutamatergic neurons of the ventral hippocampus. This study implies that KCNQ2 activators can be novel antidepressants without the ketamine side effects.
Copyright © 2022 Elsevier Inc. All rights reserved.
Conflict of interest statement
Declaration of interests Dr. Hashimoto is the inventor of filed patent applications on “The use of R-ketamine in the treatment of psychiatric diseases,” “(S)-norketamine and salt thereof as pharmaceutical,” “R-ketamine and derivative thereof as prophylactic or therapeutic agent for neurodegeneration disease or recognition function disorder,” “Preventive or therapeutic agent and pharmaceutical composition for inflammatory diseases or bone diseases,” “R-ketamine and its derivatives as a preventive or therapeutic agent for a neurodevelopmental disorder,” and “TGF-β1 in the treatment of depression” by the Chiba University. Dr. Hashimoto has also received speakers’ honoraria, a consultant fee, or research support from Abbott Russia, Daiichi-Sankyo, Meiji Seika Pharma, Seikagaku Corporation, Dainippon-Sumitomo, Taisho, Otsuka, Murakami Farm, and Perception Neuroscience (New York, USA).
Comment on
-
Ketamine exerts its sustained antidepressant effects via cell-type-specific regulation of Kcnq2.Neuron. 2022 Jul 20;110(14):2283-2298.e9. doi: 10.1016/j.neuron.2022.05.001. Epub 2022 May 31. Neuron. 2022. PMID: 35649415
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources